Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$3.15 - $5.76 $47 - $86
-15 Closed
0 $0
Q1 2021

Nov 12, 2021

SELL
$6.5 - $10.53 $162 - $263
-25 Reduced 62.5%
15 $1,000
Q4 2020

Nov 12, 2021

BUY
$3.7 - $7.66 $148 - $306
40 New
40 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Four Thought Financial, LLC Portfolio

Follow Four Thought Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Four Thought Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Four Thought Financial, LLC with notifications on news.